Hypothermia in Acute Liver Failure by Rahul Nanchal & Gagan Kumar
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










© 2013 Nanchal and Kumar, licensee InTech. This is an open access chapter distributed under the terms of 
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
Hypothermia in Acute Liver Failure 
Rahul Nanchal and Gagan Kumar 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/55629 
1. Introduction 
Acute liver failure (ALF), the manifestation of severe hepatocellular injury in the absence of 
pre-existing liver disease is a catastrophic and frequently fatal disorder. Though the injury is 
potentially reversible, the clinical course often culminates in multiple organ failure which is 
associated with a poor prognosis. The incidence is between 1 and 6 per million population 
per year [1]. However this data is predominantly from developed countries, data from 
developing countries where the etiology of ALF is very different is virtually absent. The 
most common etiologies in the developing world are hepatotrophic viruses (Hepatitis A, B 
and E) in comparison to drug induced liver failure which predominates in developed 
countries [2]. Amongst drugs, acetaminophen is the leading cause of acute liver failure and 
accounts for approximately 50% of the cases in the US [3]. Other etiologies include other 
viral infections and drugs, ischemic hepatitis, Wilson’s disease, autoimmune hepatitis, 
pregnancy related liver disorders and a large sero-negative cohort where no inciting cause 
can be identified.   
 Originally the definition of acute liver failure encompassed the development of 
coagulopathy and encephalopathy within 8 weeks of the original hepatic insult [4]. Newer 
definitions differentiate between, hyper-acute, acute and sub-acute liver failure contingent 
on the time period between the onset of jaundice and the onset of encephalopathy [5]. 
Regardless of definition used, the onset of hepatic encephalopathy especially Grade III/IV 
encephalopathy defines a turning point in the clinical course of this disease [6]. Occurrence 
of hepatic encephalopathy or coma in ALF is a poor prognostic sign and is associated with 
the development of cerebral edema, intracranial hypertension and subsequent mortality 
from brain herniation [7]. Though advances in the care of the patient with ALF have led to 
both a decrease in the incidence and associated mortality of persons developing cerebral 
edema and intracranial hypertension [7], careful vigilance should be exercised because 
development and progression of encephalopathy can be rapid and fatal. Further data on the 
declining incidence and mortality are from a single tertiary care academic center with 
 Therapeutic Hypothermia in Brain Injury 100 
immediate access to transplantation services. Such expertise may not be readily available at 
other facilities and therefore the outcomes at such centers could be considerably different. 
Moreover, cerebral edema and raised intracranial pressure in persons with ALF accounts for 
substantial mortality (between 25 and 50%) as well as neurocognitive sequalae in survivors. 
Given the devastating consequences of development of raised ICP in patients with ALF, it is 
imperative that early recognition and effective therapies be promptly instituted. 
Unfortunately prognosis in the absence of liver transplantation is dismal. Medical therapies 
are frequently utilized to control ICP as bridge to transplant. Often however medical 
therapies fail to adequately control ICP. Application of induced therapeutic hypothermia 
has shown promise in controlling ICP when medical therapies have failed. An increasing 
number of centers have incorporated hypothermia into their armamentarium of therapies to 
treat raised ICP associated with ALF as a bridge to liver transplant [8]. Emerging data also 
suggests that this modality of treatment can successfully be used as a strategy to allow for 
hepatocellular regeneration and bridge patients with ALF and cerebral edema to recovery 
[9, 10]. Timing of institution, identification of sub groups that benefit and guidelines for use 
in this condition remain unclear. This aim of this review is to highlight the pathogenesis of 
cerebral edema and attempt to elucidate the role of hypothermia is patients with ALF. 
2. Pathophysiology of cerebral edema and intracranial hypertension in 
acute liver failure 
2.1. Development of cerebral edema 
The exact pathophysiological mechanisms responsible for the occurrence of cerebral edema 
as a devastating complication of ALF are not completely elucidated. Cytotoxic edema 
appears to be the major mechanism involved in the development of cerebral edema [11, 12], 
though newer data suggest a role for vasogenic edema as well [13, 14]. Cytotoxic injury 
secondary to cellular energy failure, impaired cellular metabolism and osmoregulation 
culminates in swelling of cellular elements and accumulation of water mainly in grey 
matter. These changes involve astrocytes, microglia and neurons; however astrocyte 
swelling is a common neuropathological feature of cerebral edema in ALF. Vasogenic 
edema results as a consequence disruption of the blood brain barrier leading to leakage of 
plasma into the interstitial space and water accumulation in white matter.  
Ammonia is thought to play a central role for cytotoxic injury in this regard and is thought to 
be the most important factor leading to the formation of brain edema [15]. In animal models, 
the inhibition of glutamine synthetase, the primary brain enzyme capable of metabolizing free 
ammonia prevents formation of cerebral edema, despite further increases in brain and plasma 
ammonia levels [16]. In conditions of acute liver failure, ammonia levels rise in the plasma and 
astrocytes. In the astrocytes by the process of amidation, ammonia combines with glutamate to 
produce glutamine, a reaction catalyzed by glutamine synthetase [17]. Accumulation of 
glutamine along with hyperammonemia in astrocytes leads to osmotic alterations, oxidative 
stress, changes in the mitochondrial permeability transition, free radical production and 
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alterations in brain glucose metabolism. Together these mechanisms lead to accumulation of 
brain water and astrocyte swelling [18]. Though the aforementioned cytotoxic mechanisms 
predominate, an increasing role of vasogenic edema contributing to increased brain water and 
consequent raised intracranial pressure has been recently recognized. Although structurally 
normal the blood brain barrier becomes selectively leaky to certain polar molecules through 
subtle perturbations of the tight junctions [19]. 
2.2. Cerebral blood flow 
Cerebral blood flow is often dysregulated in ALF. Loss of auto-regulation [20] and cerebral 
hyperemia [21] are two common manifestations of ALF and encephalopathy. Systemic 
inflammatory response syndrome, particularly tumor necrosis factor has been shown to 
correlate with development of encephalopathy and raised intracranial pressure [22]. 
Cerebral hyperemia may also contribute to the development of cerebral edema. 
2.3. Raised intracranial pressure 
The combination of cerebral edema and increased cerebral blood volume from dysregulated 
cerebral blood flow lead to increased intracranial pressure in ALF.  
2.4. Clinical correlates 
Arterial ammonia concentrations greater than 100 umol/L predict the onset of hepatic 
encephalopathy [23] and concentrations greater than 200 umol/L are associated with the 
development of intracranial hypertension and subsequent brain herniation [24]. Younger 
age, development of renal failure, hyponatremia, inflammatory response and the need for 
hemodynamic support for cardiovascular collapse are additional risk factors associated with 
the development of intracranial hypertension [24]. Similarly higher cerebral blood flow rates 
are seen in patients with cerebral edema and intracranial hypertension and are associated 
with higher mortality [21].  
3. The role of hypothermia 
A growing body of experimental data and clinical data promotes the concept that induction 
of mild hypothermia (between 32 and 35 degrees centigrade) is an important therapy in the 
armamentarium against the development of cerebral edema and intracranial hypertension 
in fulminant hepatic failure. Hypothermia has been shown to either attenuate or reverse 
most pathophysiological pathways involved in the development of cerebral edema in ALF.  
3.1. Mechanism of hypothermia 
In the context of liver injury, hypothermia was first shown to be efficacious in 1962 against 
the toxicity of acute ammonia loading in mice [25]. Thereafter, Traber et al demonstrated 
that spontaneous development of hypothermia in a rat model of ALF was associated with 
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significant reductions in both cerebral edema and the time to develop encephalopathy in 
comparison to rats maintained at normal temperature [26]. This phenomenon has now been 
demonstrated in a variety of other animal models of ALF [27]. The ability of hypothermia to 
favorably affect multiple pathways of injury is probably responsible for its remarkable and 
reproducible effects on reductions of cerebrovascular complications of experimental ALF.  
The major explanatory mechanisms for the efficacy of hypothermia probably involve 
reductions in systemic and brain ammonia concentrations as well as reductions in cerebral 
blood flow. Nevertheless a variety of systemic and cerebrovascular beneficial effects have 
been proposed. 
3.2. Cerebrovascular effects 
Hypothermia, in the absence of changes in circulating concentrations of ammonia, 
independently causes lowering of brain and cerebrospinal fluid ammonia levels in mice [28]. 
Hyperammonemia in the brain causes abnormal brain metabolism of glucose, increased 
glutamine synthesis and increased oxidative stress. Abnormalities in glucose metabolism 
lead to flux down the glycolytic pathway and increased synthesis of lactate. In an animal 
model of ALF, inducing hypothermia eliminated the increased lactate and alanine 
production before decreasing cerebral edema [29]. These observations suggest that 
hypothermia mitigates abnormalities of glucose metabolism in the brain [30]. Although 
glutamine has been proposed to be the key metabolite of ammonia metabolism responsible 
for osmotic disturbances and water accumulation in the brain, prevention of brain edema by 
hypothermia was not accompanied by reductions in brain glutamine in experimental 
models of ALF. However other disturbances in other osmolytes such as myo-inositol, 
taurine, glutamate, lactate and alanine were significantly improved, leading to a better 
osmotic environment in the brain [28, 29]. Hypothermia in animal models has also lead to 
the decrement of glutamate and other amino acids in the extracellular compartment of the 
brain. Brain glutamate is known to increase in both patients [31] and in experimental ALF 
[32]. Additionally hypothermia has important anti-inflammatory properties. Inflammatory 
mediators may incrementally enhance the toxicity of ammonia resulting in worsening 
cerebral edema. Protein and m-RNA markers of a variety of pro-inflammatory cytokines 
such as IL-1 beta, TNF alpha and IL-6 have been reported to be increased in the brain of rats 
with hepatic devascularization at the time of cerebral edema [33]. Hypothermia has been 
associated with the diminution of brain efflux of such cytokines in patients and attenuation 
of cytokine production and brain edema in animals [34]. Finally reductions in body 
temperature have led to reduced markers of brain oxidative and nitrosative stress in animal 
models of ALF [35]. 
Adverse consequences of ALF on cerebrovascular hemodynamics include increased cerebral 
blood flow and loss of cerebrovascular auto-regulation. Increases in cerebral blood flow are 
both absolute as well as relative to cerebral metabolic demand. These alterations play a role 
in the development of cerebral edema and increased ICP in ALF. Therapeutic hypothermia 
reverses the increments in cerebral blood flow and restores auto-regulation in patients with 
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ALF. Hypothermia in patients with cerebral edema and raised ICP refractory to 
conventional medical therapy not only lowered ICP but also restored cerebrovascular auto-
regulation to changes in mean arterial pressure and reestablished the vasodilatory response 
to changes in partial pressure of carbon dioxide [36].  
3.3. Systemic effects 
Hypothermia consistently lowers circulating ammonia concentrations in humans and in 
animal models of ALF. In one experimental model, systemic ammonia concentrations were 
lowered by hypothermia even when hepatic detoxification was bypassed. These observation 
suggest that production of ammonia is reliant on temperature and that mechanisms of 
production are perhaps more sensitive to hypothermia than are those involved in 
detoxification.  
ALF is characterized by distributive physiology leading to elevated cardiac output and low 
systemic vascular resistance [37]. Activation of the systemic inflammatory response syndrome 
plays a pivotal role in the hemodynamic derangements of ALF [38]. Inflammation acts 
synergistically with ammonia in the development of high ICP in persons with ALF possibly 
through modulation of cerebral blood flow [39]. Hypothermia decreases systemic pro-
inflammatory cytokines in animal models as well as patients with ALF.  Hypothermia also has 
beneficial effects on systemic hemodynamics; a clinical investigation in persons with ALF and 
high ICP revealed that induction of hypothermia reduced cardiac output and raised systemic 
vascular resistance leading to diminished vasopressor requirements [40]. Thus by its potential 
of affecting both systemic hemodynamics and inflammation, hypothermia attenuates adverse 
consequences of these derangements on cerebrovascular hemodynamics. 
 
Beneficial Effects Potential Deleterious Effects 
 Improvement in cerebral edema and 
decreases in intracranial pressure 
 Decreases in brain ammonia concentration 
and uptake 
 Attenuation of brain osmolyte imbalances, 
oxidative stress and inflammatory markers 
 Decreases in cerebral blood flow and 
prevention of cerebral hyperemia 
 Restoration of cerebral blood flow auto-
regulation 
 Decreases in systemic circulating ammonia 
concentration and inflammatory markers 
 Improvements in systemic hemodynamic 
alterations 
 Attenuation of deleterious effects of 
ischemia reperfusion injury to liver 
 Decreased inter-organ ammonia production 
and trafficking  
 Increases in cerebral blood flow and 
rebound increases in ICP especially during 
rewarming phases 
 Increased risk of infections 
 Increased risk of bleeding complications 
 Cardiac arrhythmias 
 Fluid and electrolyte shifts 
 
Table 1. Brief Summary of the Effects of Hypothermia 
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Hypothermia may also attenuate liver injury. Hepatoprotective effects of hypothermia have 
consistently been demonstrated in hepatic ischemia perfusion models [41]. Reductions in 
metabolic demand, tempering of free radical production, lessening of inflammatory 
cytokines, preservation of sinusoidal cell function and improvements in the hepatic 
microcirculation are some of hepatoprotective mechanisms mediated by hypothermia. 
Similarly in a mouse model of acetaminophen induced liver injury, hypothermia attenuated 
hepatocyte damage and improved survival [42]. A brief summary of the effects of 
hypothermia is given in Table 1. 
3.4. Clinical correlates 
Despite the wealth of animal data, there has never been a randomized control trial of 
hypothermia for ALF. Most reports are from a single center and have small numbers of 
patients [9, 10, 36-40, 43, 44]. Jalan et al first reported a series of 7 patients with ALF who 
underwent hypothermia to control ICP that was refractory to medical therapy [43]. Survival 
was 75% (3/4) in patients who received a liver transplant while none of those who did not 
progress to transplant survived. However the 3 patients that were deemed unsuitable for 
receipt of a liver transplant were only cooled for 8 hours and were then rewarmed to 
baseline temperature in one hour. The same group of investigators in 2004 reported a series 
of 14 patients who were awaiting liver transplantation and had cerebral edema with 
increased ICP refractory to medical therapy. Therapeutic hypothermia was initiated and 
maintained during the surgical period. Remarkably the survival of this group of patients 
was 70% and the neurological recovery was reported to be complete [40]. Jalan et al have 
also reported a series of 16 patients undergoing liver transplantation out of which 5 had 
high ICP uncontrolled by conventional therapy [44]. The patients with high uncontrolled 
ICP underwent hypothermia which was maintained during the transplant surgery. 
Interestingly, all patients transplanted under normothermic conditions developed surges of 
high ICP during the dissection and reperfusion phases of the surgery related to cerebral 
hyperemia, whereas, this phenomenon was not observed in the hypothermia group. These 
observations are encouraging and support the use of therapeutic hypothermia in at least 
persons who develop cerebral edema as a complication of ALF and have raised ICP 
unresponsive to medical therapy. However confirmation of benefit requires a well done 
randomized controlled trial.  
The first ever RCT was recently present in abstract form in 2011 [45]. In this trial, Larsen at 
al. included 54 patients with ALF, in whom a clinical decision for ICP monitoring (imminent 
brain edema) had been made. Patients were randomized to receive standard therapy or 
therapeutic hypothermia plus standard therapy. Hypothermia was continued for 3 days. 
The authors reported no differences in outcomes of mortality, complications or the number 
of patients who developed high ICP at some point during their clinical course 
(approximately 50%). Reconciliation of these results, with results of observational studies 
suggesting major benefit, arises from the fact that persons in this study were randomized to 
hypothermia prior to the development of uncontrolled intracranial hypertension as a pre-
emptive measure. It is prudent to await the final results of this trial to provide important 
clinical direction in regards to defining the place of hypothermia in ALF.  
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The previous sections discussed the role of hypothermia in either patients who are 
candidates for liver transplantation and have high ICP that is poorly responsive to 
conventional medical therapy or in patients who are at high risk of developing 
intracranial hypertension associated with ALF. In such persons, hypothermia is used as a 
bridge to transplant. However, some reports are now emerging that suggest that this 
therapy maybe potentially be useful as a bridge to recovery in patients who are not 
candidates for liver transplantation or are at places where organs and/or transplant 
expertise is unavailable [9]. In previous investigations, rapid rewarming from 
hypothermia has been uniformly associated with rebound of high ICP, clinical 
deterioration and death [43]. Therefore instituting hypothermia as a bridge to recovery 
typically requires prolonged duration of therapy (> 100 hours) till liver recovery occurs 
and slow rewarming thereafter [9]. It should be the safety and efficacy of hypothermia is 
this particular group of patients has not been established and the evidence for use is 
circumspect at best. A summary of clinical studies examining the role and effect of 
hypothermia in acute liver failure is given in Table 2.  
 
Reference Description of Study Outcome
Jalan R et al: Lancet 
1999 
ALF with refractory elevation of ICP (> 
25 mm Hg). Total of 7 patients with 4 
listed for transplant. Hypothermia (32-
33.5 C) performed for 8-14 hours. Those 
not suitable for transplant were 
rewarmed over 1 hour to 37 C. Those 
suitable for transplant cooled through 
the transplant procedure 
3/3 unsuitable candidates for 
transplant died after 
rewarming. 1/4 transplant 
candidates died. Hypothermia 
was effective in controlling ICP 
in all patients and during 
hypothermia there were no 
significant relapses of increased 
ICP 
Jalan R et al: 
Hepatology 2001 
ALF with uncontrolled intracranial 
hypertension. 9 patients were cooled and 
cerebral hemodynamics were evaluated 
pre and 4 hours post hypothermia 
(cerebral blood flow and its auto-
regulation, reactivity to carbon dioxide 
and intracranial pressure) 
Hypothermia significantly 
lowered ICP and cerebral blood 
flow. Hypothermia restored 
defective cerebral blood flow 
auto-regulation and loss of 
reactivity to carbon dioxide that 
were observed in all patients 
pre hypothermia 
Jalan R et al: 
Transplantation 
2003 
16 patients undergoing liver transplant 
were studied and divided into three 
groups pre transplant: Group I - No 
therapy required for ICP (ICP < 15), 
Group II - ICP controlled with medical 
therapy and Group III - ICP uncontrolled 
by medical therapy and requiring 
induction of hypothermia pre transplant. 
Normothermia was maintained during 
transplant in Groups I and II and 
hypothermia (median temperature 33.4 
C) for the Group III (n=5) 
Significant increases in ICP 
were observed during the 
dissection and re-perfusion 
phase of transplant in Groups I 
and II accompanied by an 
increase in cerebral blood flow. 
In Group III neither increases in 
ICP nor cerebral blood flow 
were observed.  
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Reference Description of Study Outcome
Jalan R et al: 
Gastroenterology 
2004 
14 patients awaiting liver transplantation 
with increased ICP refractory to medical 
therapy. Hypothermia (32 – 33 C) 
performed for a median of 32 hours 
(range 10 – 118 hours) as a bridge to liver 
transplant.  
13/14 patients successfully 
bridged to transplant. 1/14 taken 
of transplant list and 
subsequently died. Significant 
decline in ICP within first hour 
of cooling that was maintained 
at 24 hours. After transplant 
10/13 patients alive at 3 months 
and had complete neurological 
recovery. 
Jacob et al: 
Neurocritical care 
2009 
Single case report of ALF and cerebral 
edema secondary to acetaminophen 
toxicity with increased ICP refractory to 
medical therapy. Hypothermia induced 
for 5 days as a bridge to liver recovery.  
Sustained decrease in ICP 
with induction of hypothermia 
that was maintained over the 
duration of hypothermia. 
Complete hepatic and 
neurological recovery 
reported  
Castillo et al: 2009 Single case report of acute liver failure 
secondary to hepatitis A virus with 
cerebral edema and elevated ICP 
refractory to medical therapy. 
Hypothermia induced for 122 hours as 
bridge to liver transplant. 
Decrease in ICP with successful 
bridge to and survival after liver 
transplant 
Holena DN et al: 
American Journal of 
Critical Care 2012 
Single case report of acetaminophen 
induced ALF who developed cerebral 
edema and elevated ICP refractory to 
medical therapy treated with 
hypothermia as a bridge to liver 
transplant. 
Decrease in ICP with 
hypothermia, improvement 
in neurological examination and 
bridge to liver transplant. 
Re-transplanted secondary to 
acute rejection and made 
complete neurological 
recovery 
Table 2. Clinical Studies Examining the Effect of Therapeutic Hypothermia in Acute Liver Failure 
Unlike cardiac arrest several questions about the induction, maintenance and rewarming 
phases of hypothermia in ALF are unanswered. Though the general principles of adequate 
sedation, avoidance of shivering, hemodynamic and other organ system monitoring as well 
as attention to fluid and electrolyte shifts remain the same, there are many issues unique to 
the patient with ALF. Particularly appropriate patient selection, risks of ICP monitoring, 
severe coagulopathy in ALF that may potentially be worsened by hypothermia, risks of 
infection, worsening cardiovascular instability and the potential deleterious effect of 
hypothermia on liver regeneration are some of the challenges faced by the clinician prior to 
instituting this therapy. If hypothermia is instituted as a bridge to liver recovery and 
subsequent resolution cerebral edema, the authors suggest that hypothermia with ICP 
monitoring be continued till there is evidence of liver recovery and that rewarming proceed 
at no more than 0.1 degrees centigrade every 2-3 hours. 
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4. Conclusions 
There is a growing body of pre-clinical and clinical literature on the utility of therapeutic 
hypothermia to control raised ICP associated with ALF. Hypothermia may be used either as 
a bridge to liver transplant or a bridge to liver recovery. However based on evidence at 
hand, it can only be recommended for control of intracranial hypertension that is 
unresponsive to conventional medical therapy. Well-designed clinical investigations are 
required to clarify the role of hypothermia in ALF. 
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